Pharmacokinetics of xylazine after 2-, 4-, and 6-hr durations of continuous rate infusions in horses

Intravenous (i.v.) bolus administration of xylazine (XYL) (0.5 mg/kg) immediately followed by a continuous rate infusion (CRI) of 1 mg kg⁻¹ hr⁻¹ for 2, 4, and 6 hr produced immediate sedation, which lasted throughout the duration of the CRI. Heart rate decreased and blood pressure increased significantly (p > .05) in all horses during the first 15 min of infusion, both returned to and then remained at baseline during the duration of the infusion. Compartmental models were used to investigate the pharmacokinetics of XYL administration. Plasma concentration–time curves following bolus and CRI were best described by a one-compartment model. No differences were found between pharmacokinetic estimates of the CRIs for the fractional elimination rate constant (K_e), half-life (t_1/2e), volume of distribution (V_d), and clearance (Cl). Median and range were 0.42 (0.15–0.97)/hr, 1.68 (0.87–4.52) hr, 5.85 (2.10–19.34) L/kg, and 28.7 (19.6–39.5) ml min⁻¹ kg⁻¹, respectively. Significant differences were seen for area under the curve ( ) (p < .0002) and maximum concentration (C_max) (p < .04). This indicates that with increasing duration of infusion, XYL may not accumulate in a clinically relevant way and hence no adjustments are required in a longer XYL CRI to maintain a constant level of sedation and a rapid recovery.     

Pharmacokinetics and Pharmacodynamics of a Depolymerized Glycosaminoglycan from Holothuria fuscopunctata,a Novel Anticoagulant Candidate,in Rats by Bioanalytical Methods

dHG-5 (Mw 5.3 kD) is a depolymerized glycosaminoglycan from sea cucumber Holothuria fuscopunctata. As a selective inhibitor of intrinsic Xase (iXase), preclinical study showed it was a promising anticoagulant candidate without obvious bleeding risk. In this work, two bioanalytical methods based on the anti-iXase and activated partial thromboplastin time (APTT) prolongation activities were established and validated to determine dHG-5 concentrations in plasma and urine samples. After single subcutaneous administration of dHG-5 at 5, 9, and 16.2 mg/kg to rats, the time to peak concentration (T_max) was at about 1 h, and the peak concentration (C_max) was 2.70, 6.50, and 10.11 μg/mL, respectively. The plasma elimination half-life(T_1/2β) was also about 1 h and dHG-5 could be almost completely absorbed after s.c. administration. Additionally, the pharmacodynamics of dHG-5 was positively correlated with its pharmacokinetics, as determined by rat plasma APTT and anti-iXase method, respectively. dHG-5 was mainly excreted by urine as the unchanged parent drug and about 60% was excreted within 48 h. The results suggested that dHG-5 could be almost completely absorbed after subcutaneous injection and the pharmacokinetics of dHG-5 are predictable. Studying pharmacokinetics of dHG-5 could provide valuable information for future clinical studies.     

Population pharmacokinetics of methadone hydrochloride after a single intramuscular administration in adult Japanese sika deer (Cervus nippon nippon)

ObjectiveTo assess the population pharmacokinetics of methadone in deer.Study designProspective non-randomized experimental trial.AnimalsTwelve healthy adult sika deer (nine males and three females).MethodsDeer received intramuscular administration of racemic methadone hydrochloride at 0.5 mg kg⁻¹ or 1 mg kg⁻¹. Plasma methadone and its metabolite 2-Ethylidene-1,5-Dimethyl-3,3-Diphenyl-Pyrolidine (EDDP) concentrations were determined by validated liquid chromatography coupled to tandem mass spectrometry methods, at times 0, 30 minutes, 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours. Population pharmacokinetics analysis was undertaken using a non-linear mixed effects modelling (NONMEM).ResultsA two-compartment linear disposition model best described observed time-concentration profiles of methadone and EDDP. Population parameter estimates of methadone were elimination clearance (17.3 L hour⁻¹), metabolic clearance (34.6 L hour⁻¹), volume of distribution of compartment 1 (216.0 L) and volume of distribution of compartment 2 (384.0 L). Population parameter estimates of EDDP were elimination clearance (121.0 L hour⁻¹), volume of distribution of compartment 3 (1.08 L) and volume of distribution of compartment 4 (499.5 L). The total clearance and total volume of distribution of methadone and EDDP were 51.9 L hour⁻¹, 121.0 L hour ⁻¹, 600.0 L and 500.6 L, respectively. The methadone terminal elimination half-life was 8.19 hours. No adverse effects were observed after methadone administration.Conclusions and Clinical relevanceFollowing intramuscular injection, methadone was characterized by a large total volume of distribution, high systemic clearance and intermediate terminal half-life in sika deer.     

Fractionated oral dosing and its effect on cyclophosphamide pharmacokinetics in dogs with high-grade multicentric lymphoma

Cyclophosphamide (CP) is an alkylating agent commonly included in multi-drug treatment protocols for canine cancer. As a prodrug, CP requires hepatic metabolism for activation to the intermediate compound 4-hydroxycyclophosphamide (4-OHCP) which then spontaneously forms alkylating phosphoramide mustard. CP is frequently administered in a fractionated manner, with the total dose given over multiple days. CP is reported to cause auto-induction of metabolism in humans, with faster CP clearance and relatively increased 4-OHCP formation following fractionated versus bolus dosing, however canine pharmacokinetic studies of CP dose fractionation are lacking. The study objective was to evaluate the pharmacokinetics of fractionated oral CP dosing at a dose of 200–250 mg/m² over 3 to 4 days in a prospectively identified population of cancer-bearing dogs. Plasma concentrations of CP and 4-OHCP were measured by ultra-high performance liquid chromatography tandem-mass spectrometry in eight dogs following the first and last doses to assess for auto-induction of CP metabolism. No significant difference in the rate of CP elimination between first and last doses were detected (0.73 ± 0.46 vs. 1.22 ± 0.5 h⁻¹; p = .125). Additionally, no significant difference in dose-normalized 4-OHCP exposure was identified between first and last doses (5.9 ± 2.1 vs. 7.9 ± 6.4 h × ng/ml; p = .936). These results suggest that fractionated dosing may not increase exposure to the active metabolite of CP in dogs as it does in humans. As such, standard bolus dosing and fractionated dosing may be equivalent in terms of bio-activation of CP in dogs administered a dose of 200–250 mg/m².     

Assessment of the long‐acting ivermectin formulation in sheep: Further insight into potential pharmacokinetic interactions

The aim of the current study was to evaluate the in vivo pharmacokinetic of ivermectin (IVM) after the administration of a long‐acting (LA) formulation to sheep and its impact on potential drug‐drug interactions. The work included the evaluation of the comparative plasma profiles of IVM administered at a single therapeutic dose (200 μg/kg) and as LA formulation at 630 μg/kg. Additionally, IVM was measured in different gastrointestinal tissues at 15 days posttreatment with both IVM formulations. The impact of the long‐lasting and enhanced IVM exposure on the disposition kinetics of abamectin (ABM) was also assessed. Plasma (IVM and ABM) and gastrointestinal (IVM) concentrations were analyzed by HPLC with fluorescent detection. In plasma, the calculated C_max and AUC_0‐t values of the IVM‐LA formulation were 1.47‐ and 3.35‐fold higher compared with IVM 1% formulation, respectively. The T_1/2ab and T_max collected after administration of the LA formulation were 2‐ and 3.5‐fold longer than those observed after administration of IVM 1% formulation, respectively. Significantly higher IVM concentrations were measured in the intestine mucosal tissues and luminal contents with the LA formulation, and in the liver, the increase was 7‐fold higher than conventional formulation. There was no drug interaction between IVM and ABM after the single administration of ABM at 15 days post‐administration of the IVM LA formulation. The characterization of the kinetic behavior of the LA formulation to sheep and its potential influence on drug‐drug interactions is a further contribution to the field.     

2种头孢氨苄片在比格犬体内的药代动力学及生物等效性试验

[目的] 研究头孢氨苄片受试制剂和参比制剂在比格犬体内的生物等效性。[方法] 采用双周期和双序列交叉设计,将22只健康比格犬随机分成2组,按30 mg/kg BW分别单剂量口服头孢氨苄片受试制剂Trolevis^®300和参比制剂Rilexine^®300,于给药前（0 h）和给药后0.5、1、1.5、2、2.5、3、4、6、8、12、17和24 h从臂头静脉采血。对超高效液相色谱串联质谱（UPLC-MS/MS）方法进行特异性、线性、检测限、准确度、精密度、稳定性等方法学考察。利用建立好的UPLC-MS/MS方法测定血浆中的药物浓度,并用WinNonlin^TM 8.1软件对药代动力学参数进行分析计算。[结果] 方法学结果显示,在100~5 000 ng/mL浓度范围内相关性良好,相关系数（R²）≥ 0.99,标准曲线方程为y=10.6828x-176.481;高、中、低3个浓度的相对回收率平均值分别为105.63%、104.35%和102.40%;日内和日间变异系数均<15%;检测限为50 ng/mL,定量限为100 ng/mL。药代动力学结果显示,参比制剂组和受试制剂组药代动力学参数如下：T_max分别为（1.77±0.55）和（2.70±4.68）h;C_max分别为（28.09±5.09）和（26.82±7.94）μg/mL;T_1/2分别为（3.39±1.43）和（3.12±1.05）h;AUC_0-t分别为（121.81±25.80）和（116.34±36.30）μg·h/mL。受试制剂与参比制剂药时曲线相似,且受试制剂与参比制剂C_max、AUC_0-t和AUC_0-∞几何均数的比值分别为99.51%、99.27%和99.30%,其90% CI均在80.00%~125.00%之间。[结论] 本试验建立的UPLC-MS/MS方法准确、可靠,可用于头孢氨苄的浓度测定,且头孢氨苄受试制剂与参比制剂是等效的,临床上均可用于相关疾病的治疗。     

兽用化学药品血药浓度法生物等效性试验技术指导原则简述

血药浓度法生物等效性试验是兽药生物等效性研究的重要方法。为科学规范兽用化学药品生物等效性研究,保障兽药安全、有效、质量可控,在已发布实施的《兽用化学药品生物等效性试验指导原则》基础上,农业农村部兽药评审中心参考相关最新技术指导原则,结合国内兽药研究现状,修订发布了《兽用化学药品血药浓度法生物等效性试验技术指导原则》。本文针对该指导原则的适用范围、试验设计的内容进行阐述,旨在加强研发单位或相关临床试验机构对此指导原则的理解,对生物等效性试验的有效开展提供指导与帮助。     

土霉素在斑节对虾体内药代动力学和生物利用度

在自然海水（盐度33）．水温为（28．0±1．0）℃养殖条件下,采用反相高效液相色谱法（RP—HPLC）,研究口灌（100mg／kg）和围心腔注射（20mg／kg）2种给药途径下,土霉素在斑节对虾（Penaeus7YlOylodoYl）体内的药代动力学和生物利用度。围心腔注射和口灌给药下,血药药时曲线均适合采用二室模型拟合。围心腔注射下血药达峰浓度（Cmax）、药时曲线下面积（AUC0-1）、消除半衰期（t,m）分别为（80．71±13．12）mg／L 378．25nag·h·L-1、17．398h;口灌给药下的相应值分别为（21．98±3．32）mg／I。324．52nag·h·L-1、23．372h,土霉素在斑节对虾体内的生物利用度（F）为17．16％。口灌土霉素后,肝胰腺Cmax为（138．655±21．375）μg／g,是血药的6．3倍、肌肉峰浓度的130．2倍,药物在肝胰腺中含量最高;然而。肌肉和肝胰腺中土霉素消除较快,消除半衰期（t1/2x）分别为28．18h和19．311 h。根据我国水产品中药物残留限量规定,水产品中土霉素的最高残留限量（NY5070—2002）为0．1mg／kg,结合本试验研究结果,斑节对虾使用土霉素后的休药期为5d,肌肉可食组织即符合无公害食品标准要求。     

盐酸诺氟沙星在奥尼罗非鱼体内的生物利用度研究

采用高效液相色谱法分别测定静脉注射和混饲口灌奥尼罗非鱼(Oreochromis aureus×O.niloticus)盐酸诺氟沙星后鱼体血液中该药含量变化,用3P97药动学软件分析药动学参数,计算生物利用度.结果表明,在(25±1)℃水温下,以10 mg/kg剂量对奥尼罗非鱼静脉注射和混饲口灌盐酸诺氟沙星,静脉注射药时...